Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?

Journal of AAPOS

Volumn 16, Issue 1, 2012, Pages 2-4

  Avery, Robert L ^a  

^a California Retina Consultants and Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

DIABETIC RETINOPATHY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LOW DRUG DOSE; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HEALTH SERVICES MISUSE; HUMANS; INFANT, NEWBORN; OFF-LABEL USE; RETINOPATHY OF PREMATURITY;

EID: 84857786747     PISSN: 10918531     EISSN: 15283933     Source Type: Journal    
DOI: 10.1016/j.jaapos.2011.11.002     Document Type: Editorial

References (26)

1. H.A. Mintz-Hittner, K.A. Kennedy, A.Z. Chuang BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity N Engl J Med 364 2011 603 615
2. D.M. Moshfeghi, and A.M. Berrocal Retinopathy of prematurity in the time of bevacizumab: Incorporating the BEAT-ROP results into clinical practice Ophthalmology 118 2011 1227 1228
3. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Epub ahead of print Dec 30 2011. Arch Dis Child Fetal Neonatal Ed.
4. D.F. Martin, M.G. Maguire CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
5. M. Tolentino Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease Surv Ophthalmol 56 2011 95 113
6. C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab Eye (Lond) 25 2011 661 672
7. R.L. Avery, J. Pearlman, and D.J. Pieramici Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 2006 1695 e1-15
8. H. Al-Dhibi, and A.O. Khan Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema J AAPOS 13 2009 400 402
9. N.R. Acharya, W. Sittivarakul, Y. Qian, K.C. Hong, and S.M. Lee Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema Retina 31 2011 1871 1876
10. I.A. Barbazetto, N. Saroj, H. Shapiro, P. Wong, A.C. Ho, and K.B. Freund Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials Am J Ophthalmol 149 2010 939 946 e931
11. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, and R.J. Singh Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 2007 855 859 (Pubitemid 46635858)
12. T. Miyake, O. Sawada, and M. Kakinoki Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes Invest Ophthalmol Vis Sci 51 2010 1606 1608
13. R.L. Avery Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern J AAPOS 13 2009 329 331
14. F. Ziemssen, Q. Zhu, and S. Peters Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: Preliminary findings of a pilot study Int Ophthalmol 29 2009 213 224
15. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Epub ahead of print Sep 17, 2011. Am J Ophthalmol.
16. K. Matsuyama, N. Ogata, M. Matsuoka, M. Wada, K. Takahashi, and T. Nishimura Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab Br J Ophthalmol 94 2010 1215 1218
17. J. Qian, Q. Lu, and Y. Tao Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy Retina 31 2011 161 168
18. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Epub ahead of print Oct 7, 2011. Am J Ophthalmol.
19. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Epub ahead of print Sep 29, 2011. Acta Ophthalmol.
20. K. Miki, A. Miki, M. Matsuoka, D. Muramatsu, S.F. Hackett, and P.A. Campochiaro Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor Ophthalmology 116 2009 1748 1754
21. H. Kim, S.B. Robinson, and K.G. Csaky FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye Mol Vis 15 2009 2803 2812
22. C. Pieh, H. Agostini, and C. Buschbeck VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity Br J Ophthalmol 92 2008 689 693 (Pubitemid 351684183)
23. G.A. Lutty, D.S. McLeod, I. Bhutto, and S.J. Wiegand Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog Invest Ophthalmol Vis Sci 52 2011 4039 4047
24. L. Yu, X.H. Liang, and N. Ferrara Comparing protein VEGF inhibitors: In vitro biological studies Biochem Biophys Res Commun 408 2011 276 281
25. Y. Kasahara, R.M. Tuder, and L. Taraseviciene-Stewart Inhibition of VEGF receptors causes lung cell apoptosis and emphysema J Clin Invest 106 2000 1311 1319
26. V. Compernolle, K. Brusselmans, and T. Acker Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice Nat Med 8 2002 702 710 (Pubitemid 34778723)